Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP707 (Adezunap) in chronic pain due to diabetic polyneuropathy
NCT06071975Phase 3Recruiting
- Sponsor
- Apurano Pharmaceuticals GmbH
- Start
- Nov 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adezunap in diabetic polyneuropathy (DPN) (2 arms), sponsored by Apurano Pharmaceuticals GmbH. Primary endpoint: Change in pain level on the Numeric Rating Scale at 14 weeks. Started Nov 2023; status: recruiting.
02
Drugs
adezunap
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT06071975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06071975.